Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 1.00 |
| ▸ | HTR2B | P41595 | 8/20 | 1.00 |
| ▸ | HTR7 | P34969 | 8/20 | 1.00 |
| ▸ | HTR2C | P28335 | 8/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nantenine SCHEMBL1254592 | 1.00 | HTR2A (1.00) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Glaucine SCHEMBL3040938 | 0.89 | HTR2A (1.00) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Glaucine SCHEMBL29735463 | 0.89 | HTR2A (1.00) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Glaucine SCHEMBL30213021 | 0.89 | HTR2A (1.00) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Glaucine SCHEMBL146441 | 0.89 | HTR2A (1.00) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| SCHEMBL5659112 | 0.88 | DRD1 (0.79) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| SCHEMBL31029794 | 0.88 | DRD1 (0.79) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Domesticine SCHEMBL29803167 | 0.88 | KDM4E (0.79) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| SCHEMBL14367903 | 0.88 | DRD1 (0.79) | HTR2AHTR2BHTR7HTR2CDRD1 | |
| Domesticine SCHEMBL1255299 | 0.88 | KDM4E (0.79) | HTR2AHTR2BHTR7HTR2CDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210137854-A1 | TAAR Receptor Agonists for the Treatment of Alopecia | JUPITER WELLNESS INC. | 2021-05-13 | — | — | US | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| WO-2020023084-A1 | TAAR RECEPTOR AGONISTS FOR THE TREATMENT OF ALOPECIA | APPLIED BIOLOGY, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| EP-2459564-A2 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | Auspex Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| US-20110306552-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | claimed |
| US-20110136861-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| WO-2011017108-A2 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| CN-1946404-A | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | CN | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136861-A1 | QUINOLONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G12A, PLA2G4A, PLA2G2A | HTR2A 492/4885HTR2B 864/4885HTR7 1716/4885 |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | HTR2A 48/4885HTR2B 44/4885HTR7 139/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2A 1/4885HTR2B 7/4885HTR7 12/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | HTR2A 48/4885HTR2B 44/4885HTR7 139/4885 |
| US-20110306552-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | HTR2A 534/4885HTR2B 1152/4885HTR7 1590/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | HTR2A 48/4885HTR2B 44/4885HTR7 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.